Keryx maintained at buy by Merrill

Merrill Lynch analyst Tom McGahren kept Keryx Biopharmaceuticals Inc. at buy on news of positive phase 2 data for Zerenex for the treatment of high phosphate levels in patients with end-stage renal disease. The 116-patient randomized study compared Zerenex at 2g, 4g and 6g per day to placebo for 28 days. Shares of the New York, N.Y.-based development stage company were up $1.01, or 7.99%, at $13.65 on volume of 1,083,018 shares versus the three-month running average of 358,642 shares. (Nasdaq: KERX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.